The estimated Net Worth of Simeon George is at least 34.6 百万$ dollars as of 27 March 2024. Simeon George owns over 2,000,000 units of Turning Point Therapeutics Inc stock worth over 34,330,601$ and over the last 11 years he sold TPTX stock worth over 0$. In addition, he makes 310,695$ as Independent Director at Turning Point Therapeutics Inc.
Simeon has made over 9 trades of the Turning Point Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 2,000,000 units of TPTX stock worth 20,000,000$ on 27 March 2024.
The largest trade he's ever made was buying 2,000,000 units of Turning Point Therapeutics Inc stock on 27 March 2024 worth over 20,000,000$. On average, Simeon trades about 151,779 units every 123 days since 2014. As of 27 March 2024 he still owns at least 451,659 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Simeon George stock trades at the bottom of the page.
Dr. Simeon J. George M.D. serves as Independent Director of the Company. Dr. George joined S.R. One Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline PLC, in 2007 as an Associate and became a Partner in 2010. Since February 2019 Dr. George has served as the Chief Executive Officer of S.R. One. From 2006 to 2007, Dr. George was a consultant at Bain & Company and in 2003 and 2004 he was an investment banker at Merrill Lynch and Goldman Sachs. In addition to our Board of Directors, Dr. George is currently a director of Crispr Therapeutics, Inc., and Principia Biopharma, Inc., both public biopharmaceutical companies, and also serves as a director on several private healthcare company boards. Dr. George was previously a director of Progyny (PGNY), Genocea (GNCA), HTG Molecular (HTGM) and Semprus Biosciences (acquired by Teleflex). Dr. George received his B.A. in Neuroscience from Johns Hopkins University, where he graduated Phi Beta Kappa. Dr. George received an M.D. from the University of Pennsylvania School of Medicine, and an M.B.A. from the Wharton School of the University of Pennsylvania.
As the Independent Director of Turning Point Therapeutics Inc, the total compensation of Simeon George at Turning Point Therapeutics Inc is 310,695$. There are 10 executives at Turning Point Therapeutics Inc getting paid more, with Yi Larson having the highest compensation of 12,579,400$.
Simeon George is 43, he's been the Independent Director of Turning Point Therapeutics Inc since 2017. There are 16 older and 3 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.
Simeon's mailing address filed with the SEC is 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE, PA, 19087.
Over the last 5 years, insiders at Turning Point Therapeutics Inc have traded over 45,947,838$ worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth 60,168,920$ . The most active insiders traders include Plc Gsk、Patrick Machado、Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of 4,727,594$. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth 88,654$.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include: